ICWEA Welcomes ViiV Healthcare’s Commitment to Triple Supply of Long-Acting HIV PrEP for Low- and Middle-Income Countries Read More
ICWEA Statement on Gilead Sciences’ Licensing of Lenacapavir: A Step Toward Expanding HIV Prevention Choices Read More
ICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention. Read More
